Cyclopharm Limited

ASX:CYC Stock Report

Market Cap: AU$167.8m

Cyclopharm Management

Management criteria checks 1/4

Cyclopharm's CEO is James McBrayer, appointed in Jun 2008, has a tenure of 16.5 years. total yearly compensation is A$893.46K, comprised of 52.7% salary and 47.3% bonuses, including company stock and options. directly owns 4.78% of the company’s shares, worth A$8.02M. The average tenure of the management team and the board of directors is 6.6 years and 2.8 years respectively.

Key information

James McBrayer

Chief executive officer

AU$893.5k

Total compensation

CEO salary percentage52.7%
CEO tenure16.5yrs
CEO ownership4.8%
Management average tenure6.6yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Oct 28
What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?

Apr 18
Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?

Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth

Mar 31
Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Oct 17
Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Jun 09
Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher

Mar 06
Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Mar 02
Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

Oct 22
We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Jun 29
Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Apr 27
Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Mar 01
Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

Feb 07
Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?

Jan 02
Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?

We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

Dec 06
We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

CEO Compensation Analysis

How has James McBrayer's remuneration changed compared to Cyclopharm's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-AU$9m

Mar 31 2024n/an/a

-AU$7m

Dec 31 2023AU$893kAU$471k

-AU$5m

Sep 30 2023n/an/a

-AU$6m

Jun 30 2023n/an/a

-AU$7m

Mar 31 2023n/an/a

-AU$7m

Dec 31 2022AU$850kAU$439k

-AU$7m

Sep 30 2022n/an/a

-AU$5m

Jun 30 2022n/an/a

-AU$4m

Mar 31 2022n/an/a

-AU$4m

Dec 31 2021AU$957kAU$427k

-AU$5m

Sep 30 2021n/an/a

-AU$5m

Jun 30 2021n/an/a

-AU$4m

Mar 31 2021n/an/a

-AU$5m

Dec 31 2020AU$1mAU$406k

-AU$6m

Sep 30 2020n/an/a

-AU$6m

Jun 30 2020n/an/a

-AU$6m

Mar 31 2020n/an/a

-AU$4m

Dec 31 2019AU$753kAU$341k

-AU$3m

Sep 30 2019n/an/a

-AU$3m

Jun 30 2019n/an/a

-AU$2m

Mar 31 2019n/an/a

-AU$1m

Dec 31 2018AU$426kAU$335k

-AU$35k

Sep 30 2018n/an/a

-AU$409k

Jun 30 2018n/an/a

-AU$782k

Mar 31 2018n/an/a

-AU$1m

Dec 31 2017AU$421kAU$327k

-AU$2m

Compensation vs Market: James's total compensation ($USD558.80K) is above average for companies of similar size in the Australian market ($USD291.73K).

Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.

CEO

James McBrayer (59 yo)

16.5yrs

Tenure

AU$893,462

Compensation

Mr. James S. McBrayer, BSPharm, GDM, FAICD, AIM, has been the Managing Director at Cyclopharm Ltd. since June 3, 2008 and also serves as its Chief Executive Officer. Mr. McBrayer has been Company Secretary...

Leadership Team

NamePositionTenureCompensationOwnership
James McBrayer
CEO, MD16.5yrsAU$893.46k4.78%
A$ 8.0m
Mathew Farag
Chief Operating Officer7.9yrsAU$484.33k0.45%
A$ 755.0k
Graham Phillips
Finance Managerno dataAU$152.73kno data
Sally-Ann Cornelius
Head of Sales5.3yrsno datano data
Niamh McAree
Head of Quality and Regulatory5.3yrsno datano data
Chris Quinn
Head of Service5.3yrsno datano data
Sui Cheah
Financial Controller13.8yrsAU$64.44kno data
Lynn McLauchlin
General Manager of Canadano dataAU$173.42kno data
Gary Somerville
Quality & Regulatory Managerno dataAU$151.96kno data

6.6yrs

Average Tenure

Experienced Management: CYC's management team is seasoned and experienced (6.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
James McBrayer
CEO, MD16.5yrsAU$893.46k4.78%
A$ 8.0m
Dianne Angus
Independent Non-Executive Director3.3yrsAU$60.76k0.020%
A$ 33.7k
David Heaney
Independent Non-Executive Chairman18.1yrsAU$85.07k0.27%
A$ 454.7k
John Wigglesworth
Non-Executive Directorless than a yearno data0.049%
A$ 81.5k
Kevin M. Barrow
Independent Non-Executive Director2.3yrsAU$60.76k0.023%
A$ 37.9k
Gregory King
Independent Non-Executive Director2.3yrsAU$60.76k0.0090%
A$ 15.1k

2.8yrs

Average Tenure

64yo

Average Age

Experienced Board: CYC's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 06:35
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cyclopharm Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightBarclay Pearce Capital Pty Limited
John HesterBell Potter
Sarah MannMA Moelis Australia Securities Pty Ltd